Physician profile
Paul D Lyons
NPI 1083656250
$171,433.63
in general payments reported to CMS, 2019-2025
76 companies · $15K in 2025
The $15K reported for 2025 was more than what 90% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $28K · 2021: $24K · 2022: $24K · 2023: $21K · 2024: $30K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $13K · Travel and Lodging: $5,991 · Consulting Fee: $2,280 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,142.00 |
| Food and Beverage | $12,768.65 |
| Travel and Lodging | $5,990.85 |
| Consulting Fee | $2,280.00 |
| Education | $186.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $85,277.39 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Sk Life Science, INC. | $25,793.29 | 2020-2025 | Xcopri |
| Greenwich Biosciences, INC. | $19,000.41 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $11,729.36 | 2021-2025 | |
| Livanova USA, INC. | $11,128.13 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $5,497.32 | 2020-2025 | Valtoco |
| Abbvie INC. | $1,112.19 | 2021-2025 | |
| Biogen, INC. | $952.98 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Lilly USA, LLC | $724.41 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Novartis Pharmaceuticals Corporation | $634.27 | 2019-2025 | |
| Eisai INC. | $604.40 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $591.06 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $577.72 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $454.79 | 2019-2020 | |
| Neuropace, INC. | $446.58 | 2019-2024 |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $437.74 | 2019-2025 | |
| Lundbeck LLC | $421.59 | 2019-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $415.50 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $354.72 | 2019-2025 | Uplizna, Aimovig |
| Medtronic, INC. | $269.39 | 2023-2025 | Percept Pc Brainsense |
| Inspire Medical Systems, INC. | $243.66 | 2023-2025 | Inspire |
| Ani Pharmaceuticals, INC. | $240.46 | 2022-2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $227.18 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Sunovion Pharmaceuticals INC. | $209.39 | 2019-2022 | |
| Allergan, INC. | $190.71 | 2019-2022 | |
| Emd Serono, INC. | $182.36 | 2022-2025 | Mavenclad |
| Mdd US Operations, LLC | $178.72 | 2022-2024 | Gocovri, Gocovri |
| Tanabe Pharma America, INC. | $170.32 | 2022-2025 | Radicava |
| Abbott Laboratories | $148.86 | 2019-2025 | Infinity |
| Horizon Therapeutics Plc | $144.25 | 2021-2023 | Uplizna |
| Cadwell Industries, INC | $143.20 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $141.05 | 2023-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Microtransponder, INC. | $138.80 | 2024 | |
| Celgene Corporation | $132.92 | 2021-2024 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $132.65 | 2021-2025 | |
| Tg Therapeutics, INC. | $132.41 | 2023-2025 | |
| Biocodex, INC. | $132.31 | 2025 | |
| Argenx US, INC. | $126.64 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Kyowa Kirin, INC. | $119.81 | 2021-2024 | Nourianz |
| Acorda Therapeutics, INC | $119.31 | 2019-2023 | Ampyra, Inbrija |
| Csl Behring | $115.62 | 2019-2023 | Hizentra |
| Avanir Pharmaceuticals, INC. | $112.46 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $107.38 | 2024-2025 | Acthar |
| Zoll Respicardia, INC. | $107.28 | 2023 | Remede System |
| Merz Pharmaceuticals, LLC | $89.62 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Harmony Biosciences LLC | $88.82 | 2020-2025 | |
| Monteris Medical Corporation | $87.57 | 2022 | |
| Zogenix INC. | $85.82 | 2021 | |
| Grifols USA, LLC | $74.55 | 2019 | |
| Sumitomo Pharma America, INC. | $73.99 | 2023-2024 | Aptiom |
| Biohaven Pharmaceutical Holding Company Ltd. | $73.86 | 2022 | |
| Ge Healthcare | $65.42 | 2025 | |
| Axsome Therapeutics, INC. | $65.30 | 2023-2024 | Sunosi |
| Vanda Pharmaceuticals INC. | $59.62 | 2025 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $55.04 | 2023-2024 | Nuedexta, Rexulti |
| Janssen Pharmaceuticals, INC | $53.80 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $49.07 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $40.35 | 2019-2022 | |
| Immedica Pharma US, INC. | $38.57 | 2023 | |
| Acadia Pharmaceuticals INC | $37.08 | 2024 | Nuplazid |
| Astrazeneca Pharmaceuticals Lp | $33.72 | 2024-2025 | Wainua |
| Adamas Pharmaceuticals, INC. | $32.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.00 | 2025 | Zeposia |
| Merz North America, INC. | $28.91 | 2019 | |
| Boston Scientific Corporation | $26.11 | 2024 | Watchman Access System |
| Nevro Corp. | $22.12 | 2021 | |
| Banner Life Sciences, LLC | $21.13 | 2021 | |
| Corium, LLC | $18.10 | 2023 | Adlarity |
| Biohaven Pharmaceuticals, INC. | $17.45 | 2021 | |
| Currax Pharmaceuticals LLC | $14.03 | 2020 | |
| Impel Pharmaceuticals INC. | $13.73 | 2022 | |
| Mallinckrodt Enterprises LLC | $13.50 | 2019 | |
| Travere Therapeutics, INC. | $1.17 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.